NCT07049341
Pilot Trial Evaluating Patient Experience With the MemorEM for Patients With Neurological Diseases
Enrolling by Invitation
NAAges 45+InterventionalNeuroEM Therapeutics, Inc.
~100 participants
Updated 2025-08-05 on ClinicalTrials.gov
What's tested:MemorEM
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patient and caregiver reports on device design and use
Measured over Surveys will be given starting a month after beginning treatment and monthly thereafter over the course of up to two years.
Conditions
Where it's being run
1 sites across 1 statesFlorida1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patient diagnosed with a neurological disease involving aggregated proteins such as Alzheimer's and its variants, Parkinson's, Frontotemporal dementia, Amyotrophic lateral sclerosis, Tauopathies, and other related neurological diseases.
Presence of a caregiver(s) responsible for ensuring treatment compliance and potentially with authority to make medical decisions for the patient if the patient is not competent to make those decisions
Willing to sign NeuroEM's patient consent form
Exclusion
Patient has uncontrolled: Seizures, Epilepsy, Depression, Bipolar disorder, psychotic disorders, alcoholism or drug addiction
Presence of metal implants in the head, except for metal dental implants
Patient has hypertension that is unresponsive to anti-hypertensive medications
Patient has implanted medication pumps unless cleared by physician
Patient has significant heart disease, as determined by a physician
What this trial measures
- Patient and caregiver reports on device design and useSurveys will be given starting a month after beginning treatment and monthly thereafter over the course of up to two years.
The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device. This information will be gathered via a monthly survey. This information may help in new designs of the MemorEM and suggest ways to increase compliance for future clinical trials and eventual commercialization.